LIFE SCIENCES
Boston-Haifa Life Sciences Initiative (BHLSI)

Boston-Haifa Connection

MATI HAIFA
Haifa Small Business Development Center

BHLSI Boston BioDelegation 2007
Sunday, October 28 - Wednesday, October 31, 2007
Boston, Massachusetts

The Boston-Haifa Life Sciences Initiative (BHLSI)

B2B PROGRAM
2007 Company Highlights

The Boston-Haifa Life Sciences Initiative (BHLSI), established in 2004 by CJP Boston Haifa Connection in collaboration with the Haifa Municipality, Mati Haifa and local organizations, catalyzes collaborations in order to help grow the Haifa economy through the life sciences. To achieve the promise of economic health in Haifa via the life sciences sector, BHLSI facilitates connections and opportunities for coaching, mentoring and targeted cross border connections for research and business collaborations, technology transfer, strategic alliances, joint ventures and syndicated investment in Israel's innovative and knowledge-driven life sciences sector. Companies enrolled in the BHLSI B2B program are carefully reviewed by a voluntary bi-national team of experts. Each enrolled company has been developed by and/or in affiliation with top leading medical experts in Israel.

BHLSI 2007 Companies

BIOAIM LTD.

BioAim will establish a full-service, commercially oriented large animal testing facility in Israel that will provide growing life science companies with an accessible alternative to satisfy their research and development needs. The well-equipped facility for conducting pre-clinical trials on large animals will contain a fully outfitted surgical unit for performing a full range of procedures, including x-ray and fluoroscopy, and will be planned and constructed at a highly professional standard to allow GLP certification. It will be located so as to allow easy access by companies from central and northern Israel, and will provide testing facilities, including toxicology studies, as well as services such as modeling of animal experiments and quality assurance.

BIOHUG TECHNOLOGIES LTD.

BioHug Technologies, Ltd. is developing a wearable calming system. The initial audience for the device is people with autism, ADHD and related conditions. The BioHug device is designed to deliver deep pressure therapy and pulsation automatically and to be light and easily portable. It consists of a therapeutic vest and will use biometric measurement to make it completely self regulating, providing an effective, non-drug method for calming agitated people.

Prepared by Robin JR Blatt I CJP Life Sciences Project I 617.633.5522 I robinblatt@biogenuity.com
Michal Lotem I Mati Haifa I michal@mati.co.il

BHLSI Boston BioDelegation 2007
Sunday, October 28 - Wednesday, October 31, 2007
Boston, Massachusetts

BRAIN TECH LTD.

BrainTech Ltd. is a life sciences company that develops a unique and objective approach to interpret the Heart Rate Variability (HRV) physiological parameter as an indication of major psychiatric disorders, including schizophrenia, major depression and anxiety disorders. The U.S. economy loses over $147 billion each year as a result of misdiagnosed and under treated psychiatric disorders (ADAA, NIMH). The application of Braintech's technology will, for the first time, allow psychiatrists, clinical psychologists and primary care physicians, or organizations who require screening of population, to objectively assess and diagnose a psychiatric state, its type, and the severity in an accurate and uniform manner.

HERNIA SOLUTIONS LTD.

Hernia Solutions is a medical device company dedicated to developing and commercializing gold standard solutions for hernia repair. Over two million hernia repairs are performed annually worldwide, making hernia repair one of the most common procedures preformed by general surgeons. In less than 3 months, the company has demonstrated preclinical technology proof-of-concept, and has designed three innovative products. The first product is a mesh spreading and fixating device for ventral and umbilical laparoscopic hernia repair. It will reduce procedure time by up to an hour, and is expected to reach the market by Q4 2008.

IMMUNARRRAY LTD.

ImmunArray Ltd. is developing a novel in-vitro diagnostic platform system -- which consists of microarrays, proprietary software and a table top instrument -- for prediction, early diagnosis, personalized treatment selection and patient monitoring of immune-related disorders, including auto-immune diseases, cancer, inflammatory and degenerative diseases. A line of products based on ImmunArray's technology will be developed, each dedicated to a specific clinical indication, leading to earlier diagnosis and more accurate treatment selection, resulting in a profound effect on patient survival and quality of life as well as on healthcare costs. ImmunArray's system will require only minute amounts of blood, will be amenable to automation and will be suitable for use as a screening test of large populations. Founded in October 2005 under the auspices of RAD Biomed, a privately held Technology Incubator in Israel, ImmunArray holds exclusive, world-wide license from the Weizmann Institute of Science to develop and to commercialize the Immuno-Chip technology developed by Profs. Irun Cohen and Eytan Domany, who act, respectively, as ImmunArray's Chief Science Officer and member of the Scientific Advisory Board. ImmunArray has completed proof-of-concept studies in a number of applications of its platform technology and seeks funding to complete its first product, a blood test for the early diagnosis and management of lung cancer, as well as strategic partners for bringing this test to the market.

Prepared by Robin JR Blatt I CJP Life Sciences Project I 617.633.5522 I robinblatt@biogenuity.com
Michal Lotem I Mati Haifa I michal@mati.co.il

JETGUIDE LTD.

Bone drilling is an inexact and, often, blind art. During bone drilling procedures, surgeons do not know the precise location of their drill tip in relation to nerves or blood vessels. JetGuide's intraoperative bone drilling monitoring system complements pre-procedure imaging techniques (CT, MRI, and panoramic x-ray), advancing bone drilling to a higher level with real-time intraoperative monitoring throughout the drilling process. JetGuide's proprietary ultrasonic technology provides surgeons with intraoperative feedback on the distance between the bottom of the drilled bore and sensitive tissues. The easy-to-use, cost effective system takes the guesswork out of drilling, enabling surgeons to drill into bone without fear of harming nerves and blood vessels. The result: greater surgeon confidence and significantly improved patient outcomes. JetGuide's first application is an add-on to existing dental implant drills where intraoperative monitoring is of great importance to surgeons performing dental implantation surgery. Development of an advanced prototype has been completed and the company will enter clinical trials by the end of 2007. JetGuide Ortho-Spine tools will aid orthopedic and spine surgeons reduce complications and improve patient outcomes for spinal fusion procedures, hip, pelvis, shoulder fractures, and complex fractures in the lower extremities.

Keren Medical KEREN MEDICAL LTD.

Keren Medical Ltd. is developing innovative technology to facilitate the urethro-vesical anastomosis in laparoscopic, robotic and open radical prostatectomy. Laparoscopic anastomosis often results in prolonged postoperative urine leak, urinary incontinence and outflow obstruction. Products based on Keren's technology will allow surgeons to perform a rapid watertight anastomosis resulting in early recovery and postoperative continence.

MINIMALLY INVASIVE MASTOPEXY (MIM) MEDICAL LTD.

MIM is developing an innovative technology for reshaping, supporting, and lifting soft tissue body parts for aesthetic reasons. The first product is an innovative technology for breast lifting, MIM's Cup&Up™ breast lifting kit is intended to revolutionize the field of cosmetic breast surgery by replacing the breast lifting procedure (mastopexy). The target markets for MIM's Mastopexy procedure is the existing mastopexy market as it's the only

Prepared by Robin JR Blatt I CJP Life Sciences Project I 617.633.5522 I robinblatt@biogenuity.com
Michal Lotem I Mati Haifa I michal@mati.co.il

solution for early stage of breast sagging; and, in conjunction with breast reduction procedures, MIM intends to dominate this new market by forming strategic partnerships with leading manufacturers and distributors of medical equipment for the cosmetic surgery industry. MIM expects to launch it first product in Brazil and Europe (the largest markets with the highest adoption rate for cosmetic procedures).

ULTRASURGE TECHNOLOGIES LTD.

UltraSurge Technologies has developed and patented a novel SMART-JETsurgical system based on smart saline jet technologies, which enable preciseand selective tissues removal and sealing of blood vessels, using controlled thin pairs of high pressure convergent saline-jets. The SMART-JET constitutes the next generation device in minimally invasive surgeries, as it enables "cold" dissection, selective tissue removal, and sealing of blood vessels to be performed concomitantly, therefore providing cost-effective, precise and less traumatic treatment to various endoscopic and laparoscopic procedures with improved treatment safety and reduced operation time, while minimizing associated pain and complications. The Company focuses initially on two applications/markets: BPH treatment, and the Gynecological tissue removal procedures. Each of these alone represents a huge potential market in replacing currently available solutions and methods. UltraSurge has completed successful Ex-vivo BHP trials and is currently in a process of making the necessary steps for obtaining the Helsinki approvals in order to initiate multi-central clinical trials in Israel and abroad as part of the
regulatory clearance processes (CE-Mark and FDA).

Prepared by Robin JR Blatt I CJP Life Sciences Project I 617.633.5522 I robinblatt@biogenuity.com
Michal Lotem I Mati Haifa I michal@mati.co.il